Efficacy, safety and compliance — three points of success in cholesterol lowering

M.L. Maximov¹, A.G. Obrezan^2,3, I.S. Burashnikova¹, A.A. Shikaleva¹

¹Kazan State Medical Academy, the branch of the Russian Medical Academy of Continuing Professional Education

²St. Petersburg State University

³MMC SOGAZ LLC, St. Petersburg

One of the leading factors in cardiovascular diseases pathogenesis is dyslipidemia, which contributes significantly to the overall mortality, including from its pathology. Statins, and in particular rosuvastatin, are the first-line drugs in hyperlipidemia, providing a clinically significant reduction in atherogenic lipoproteins. It has been repeatedly shown that cholesterol (CS) target levels achievement of low density lipoproteins (LDL) leads to a significant reduction in the cardiovascular complications risk and savings in health care costs. Ezetimibe addition to rosuvastatin leads to a more pronounced decrease in LDL CS and is safer against adverse drug reactions, compared with an increase in the statins dosage in monotherapy. Significantly more patients treated with the rosuvastatin + ezetimibe combination, compared with rosuvastatin monotherapy, a chieve the CS target level of non-high density lipoproteins, due to the fact that both drugs work synergistically. This fixed combination increases compliance and gives the physician more confidence that the patient will continue to follow the prescribed therapy. The combination of rosuvastatin with ezetimibe in the drug Rosulip^® Plus can be considered as the combination of choice from clinical and economic point of view in patients with high and very high cardiovascular risk dyslipidemia.

Keywords: dyslipidemia, statins, fixed combination of rosuvastatin with ezetimibe, treatment efficacy of cardiovascular diseases, lipid-lowering therapy safety, Rosulip Plus.

For citation: Maximov M.L., Obrezan A.G., Burashnikova I.S., Shikaleva A.A. Efficacy, safety and compliance — three points of success in cholesterol lowering. RMJ. 2019;8(I):41–45.